Progression and natural history of Atypical Parkinsonism (ATPARK): Protocol for a longitudinal follow-up study from an underrepresented population.

Journal: PloS one
Published Date:

Abstract

BACKGROUND: Atypical Parkinsonian Syndromes (APS) form the third largest group of neurodegenerative disorders including Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), and Corticobasal Syndrome (CBS). These conditions are characterized by rapid progression, poor prognosis, low survival rates, and limited treatment options. Few studies have suggested that genetic, environmental factors and inflammation contribute to the pathobiology of these complex disorders, however, the etiology of disease and progression remains unclear.

Authors

  • Ravi Yadav
    Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, India.
  • Saikat Dey
    Department of Human Genetics, National Institute of Mental Health and Neurosciences, Bangalore, India.
  • Ravichandiran Kumar
    Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, India.
  • Athira P Mohanan
    Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, India.
  • Geethu T Vasudevan
    Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, India.
  • Manasi Harish
    Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, India.
  • Nitish Kamble
    Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, India.
  • Vikram V Holla
    Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, India.
  • Rohan R Mahale
    Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, India.
  • Pooja Mailankody
    Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, India.
  • Monojit Debnath
    Department of Human Genetics, National Institute of Mental Health and Neurosciences, Bangalore, India.
  • Jitender Saini
    Department of Neuroimaging & Interventional Radiology, National Institute of Mental Health and Neurosciences, Bangalore, India.
  • Keshav Kumar
    Department of Clinical Psychology, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, Karnataka, India.
  • Anita Mahadevan
    Department of Neuropathology, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, Karnataka, India.
  • Sarada Subramanian
    Department of Neurochemistry, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, Karnataka, India.
  • Phalguni Alladi
    Department of Clinical Psychopharmacology and Neurotoxicology, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, Karnataka, India.
  • Indrani Datta
    Department of Biophysics, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, Karnataka, India.
  • Binu V Sreekumarannair
    Department of Biostatistics, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, Karnataka, India.
  • Priya Thomas
    Department of Oral Pathology and Microbiology, Annoor Dental College and Hospital, Muvattupuzha, Ernakulam, Kerala, India.
  • Anish Mehta
    Department of Neurology, Ramaiah Medical College and Hospitals, Bangalore, India.
  • Albert Stezin
    Clinician Scientist, Indian institute of Science, Centre for brain research, Bangalore, India.
  • Madhura Ingalhalikar
    Symbiosis Center of Medical Image Analysis, Symbiosis International (Deemed) University, Pune, India. Electronic address: head@scmia.edu.in.
  • Sweta Ramdas
    Indian Institute of Science, Bangalore, India.
  • Deepthi R Bathula
    Department of Computer Science and Engineering, Indian Institute of Technology Ropar, Bara Phool, Punjab, India.
  • Pramod Kumar Pal
    Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, India.